rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    CELC
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Celcuity at Jefferies Global Healthcare Conference: launch gains, hurdles remain
      13h agoInvesting.comCELCJEF
      Celcuity at guggenheim healthcare innovation conference: launch gains pace
      Nov 10Investing.comCELC
      FDA accepts Celcuity application for expanded breast cancer use
      Nov 9Investing.comCELC
      Citizens reaffirms Celcuity stock rating on competitive positioning
      Nov 9Investing.comCELC
      Celcuity Inc (CELC) Q3 2026 Earnings Call Highlights: Revtorpic's Strong Launch Momentum Meets ...
      Nov 6Yahoo FinanceCELC
      What Celcuity (CELC) Said on Its Q3 Earnings Call
      Nov 6Yahoo FinanceCELC
      Celcuity Q3 2026 Earnings Call Transcript
      Nov 5BenzingaCELC
      Celcuity Inc. Reports Third Quarter 2026 Financial Results and Provides Corporate Update
      Nov 5Yahoo FinanceCELC
      Celcuity: Stronger Clinical Evidence, Much Lower Valuation (NASDAQ:CELC)
      Oct 30Seeking AlphaCELC
      Celcuity Schedules Release of Third Quarter 2026 Financial Results and Webcast/Conference Call
      Oct 29Yahoo FinanceCELC
      Citizens reiterates Celcuity stock rating on cancer trial data
      Oct 28Investing.comCELC
      Will Breast And Prostate Cancer Data Change Celcuity (CELC) Narrative
      Oct 25Yahoo FinanceCELC
      Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026

      Median PFS was 21.5 months with the gedatolisib triplet and 11.5 months with the gedatolisib doublet versus 9.1 months with alpelisib + fulvestrant in patients who had no liver metastases ORR and median duration of response was 59% and 19.4 months for the gedatolisib triplet and 43% and 27.8 months for the gedatolisib doublet, respectively, compared to 33% and 7.5 months for alpelisib + fulvestrantThe discontinuation rate for gedatolisib due to treatment-emergent adverse events was 5% and 4% wit

      Oct 24Yahoo FinanceCELC
      Celcuity reports phase 1b prostate cancer trial results
      Oct 23Investing.comCELC
      Celcuity Presents Updated Data from a Phase 1b/2 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration-Resistant Prostate Cancer at the ESMO Congress 2026
      Oct 23Yahoo FinanceCELC
      Cantor sees ‘credible path to multi-billion-dollar peak sales’ for Celcuity
      Oct 22Investing.comCELC
      Cantor Fitzgerald Initiates Celcuity at Overweight With $140 Price Target
      Oct 22Yahoo FinanceCELC
      Cantor Fitzgerald initiates Celcuity stock with overweight rating
      Oct 22Investing.comCELC
      Celcuity stock price target raised to $145 by TD Cowen on uptake
      Oct 21Investing.comCELC
      Citizens reiterates Celcuity stock rating on ESMO data presentation
      Oct 19Investing.comCELC
      Celcuity (CELC) Stock May Be Hard To Value On Book Value
      Oct 18Yahoo FinanceCELC
      how InvestingPro’s Fair Value flagged Celcuity’s 52% decline By Investing.com
      Oct 13Investing.comCELC
      Celcuity (CELC) Is Down 17.3% After REVTORPYK US Launch And sNDA Filing News Event
      Oct 8Yahoo FinanceCELC
      Celcuity to present gedatolisib trial data at ESMO congress
      Oct 5Investing.comCELC
      Celcuity Announces Multiple Presentations At The European Society For Medical Oncology (ESMO) Congress 2026

      Rapid oral presentation of additional sub-group analyses from the VIKTORIA-1 PIK3CA mutant-type cohort Poster presentation of a comparative analysis of data for the gedatolisib triplet from the PIK3CA wild-type cohort of VIKTORIA-1 and other regimens evaluated in patients with HR+/HER2- advanced breast cancer Poster presentation of sub-group analyses from the Phase 1b trial of gedatolisib plus darolutamide in patients with mCRPC MINNEAPOLIS, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasda

      Oct 5Yahoo FinanceCELC
      Celcuity (CELC) Dropped, So What Is Behind Its Latest Move?

      Celcuity (CELC) has moved into a new phase, with REVTORPYK now commercially available in the US for certain advanced breast cancer patients, paired with a support program that targets access, affordability, and treatment logistics. Despite REVTORPYK’s US launch and the recent appointment of seasoned finance leader David W. Gryska to Celcuity’s board, the share price has pulled back, with the 30 day share price return down 25.1% and the 1 year total shareholder return still up 42.7%. This...

      Oct 3Yahoo FinanceCELC
      Celcuity appoints David Gryska to board of directors
      Oct 2Investing.comCELC
      Celcuity Appoints David Gryska To Its Board Of Directors

      Mr. Gryska brings decades of strategic and financial leadership experience to Celcuity’s BoardMINNEAPOLIS, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications, today announced the appointment of David W. Gryska to its Board of Directors. Mr. Gryska is a seasoned executive who brings over 35 years of strategic and financial leadership experience in

      Oct 2Yahoo FinanceCELC
      Why Celcuity Stock Was a Winner on Wednesday | The Motley Fool

      Its first commercialized drug is now available for qualified patients.

      Sep 30The Motley FoolCELC
      Celcuity launches Revtorpyk for advanced breast cancer in US
      Sep 30Investing.comCELC
      Celcuity Announces That REVTORPYK™ (gedatolisib) Is Now Commercially Available In The United States
      Sep 30Yahoo FinanceCELC
      Why is Celcuity stock climbing today?
      Sep 17Investing.comCELC
      JPMorgan Initiates Celcuity With Overweight Rating, $157 Price Target

      Celcuity (CELC) has an average rating of buy and mean price target of $160.75, according to analysts

      Sep 17Yahoo FinanceCELC
      JPMorgan initiates Celcuity stock coverage with overweight rating
      Sep 17Investing.comCELC
      Celcuity at citigroup’s biopharma back to school summit: launch begins
      Sep 9Investing.comCELCC
      Celcuity at Wells Fargo healthcare conference: launch, data in focus
      Sep 8Investing.comCELCWFC
      Celcuity To Participate in Upcoming Investor Conferences

      MINNEAPOLIS, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications, today announced that Brian Sullivan, Chief Executive Officer and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following investor conferences: A fireside chat at the Wells Fargo 21st Annual Healthcare Conference at 10:15 a.m. EDT on T

      Sep 1Yahoo FinanceCELC
      Celcuity (CELC): Landmark Approval Collides With A Costly Launch

      On August 13, Celcuity (NASDAQ:CELC) walked investors through a quarter unlike any in the company’s history. The clinical-stage biotech is no longer just clinical: its breast cancer drug Revtopik won FDA approval on July 14, and the call was built around how the company plans to turn that approval into an actual business. The tone […]

      Aug 27Yahoo FinanceCELC
      Celcuity submits application for breast cancer drug expansion
      Aug 26Investing.comCELC
      Celcuity Submits sNDA to FDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer

      If approved, REVTORPYK would be the first and only therapy for advanced breast cancer with a PIK3CA mutation that inhibits all class I PI3K isoforms (α, β, δ, γ) and mTOR complexes mTORC1 and mTORC2 MINNEAPOLIS, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for multiple solid tumor indications, today announced the submission of its supplemental New Drug Application (“sNDA”) to the U.S. Food and

      Aug 26Yahoo FinanceCELC

      This is the newest page. Registered accounts read further back.